The Janssen Pharmaceutical Companies of Johnson & Johnson announced the results from the Phase 3 COLUMBA study, investigating a subcutaneously (SC) administered formulation of DARZALEX®(daratumumab), co-formulated with recombinant human hyaluronidase PH20...